Press Releases Latest Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose Nov 24, 2023 Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement Oct 24, 2023 Theratechnologies Announces Operational Update Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon Oct 13, 2023 Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs) Oct 13, 2023 Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 21 - 30 of 360
Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
Oct 13, 2023 Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Oct 13, 2023 Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study